/HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options
NEWS
HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options
PRNewswire
2025/05/30Dr. Matthias Preusser presenting the TUXEDO-3 trial
Summary
The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast or...